BO44157 Flashcards

1
Q

RO7247669

A

Anticorps bispécifique LAG-3 et PD-1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Tiragolumab

A

Anti TIGIT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Design

A

Essai de phase II randomisé

Atezolizumab (antiPDL1)
Vs
combinaison Tiragolumab et RO7247669
Vs
RO7247669

Randomisation 1:1:1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Critère de jugement principal

A

ORR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Sélection des patients

A

Carcinome urothelial métastatiques inéligibles au platine en 1ere ligne (> de 12 mois après néoadjuvant)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Critères inégilité a tous les platines selon l’étude

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Criteres inclusions : corticoides snc et créat

A

créat : 15mL min
SNC : possible si controlé
Corticoides: pas possible sauf si faibles doses et ttt court

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Evaluations tumorales

A

toutes les 6 semaines jusqu’à 12 semaines puis toutes les 9 semaines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly